Based on the Guardant Health Inc stock forecast from 13 analysts, the average analyst target price for Guardant Health Inc is USD 42.67 over the next 12 months. Guardant Health Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Guardant Health Inc is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Guardant Health Inc’s stock price was USD 31.67. Guardant Health Inc’s stock price has changed by -8.89% over the past week, +3.23% over the past month and +25.57% over the last year.
No recent analyst target price found for Guardant Health Inc
No recent average analyst rating found for Guardant Health Inc
Company Overview Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California. Read Less
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test...Read More
Frequently Asked Questions About Guardant Health Inc (GH) Stock
Based on ratings from 13 analysts Guardant Health Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 15 buy, sell and hold ratings.
Unfortunately we do not have enough data on GH's stock to indicate if its a good dividend stock.
Based on targets from 13 analysts, the average taret price for GH is USD 42.67 over the next 12 months. The maximum analyst target price is USD 60 while the minimum anlayst target price is USD 32.
GH stock's Price/Earning ratio is 10.05.
Our analysis grades GH stock's Price / Earning ratio at D. This means that GH stock's Price/Earning ratio is above 36% of the stocks in the Diagnostics & Research sector in the NSD exchange.
Based on this GH may be fairly valued for its sector
The last closing price of GH's stock was USD 31.67.
The most recent market capitalization for GH is USD 4.40B.
Based on targets from 13 analysts, the average taret price for GH is projected at USD 42.67 over the next 12 months.
This means that GH's stock price may go up by +34.72% over the next 12 months.
We can't find any ETFs which contains Guardant Health Inc's stock.
As per our most recent records Guardant Health Inc has 1,768 Employees.
Guardant Health Inc's registered address is 3100 Hanover Street, Palo Alto, CA, United States, 94304.
You can get more information about it from Guardant Health Inc's website at https://guardanthealth.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Guardant Health Inc (GH) Stock
Based on ratings from 13 analysts Guardant Health Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 15 buy, sell and hold ratings.
Unfortunately we do not have enough data on GH's stock to indicate if its a good dividend stock.
Based on targets from 13 analysts, the average taret price for GH is USD 42.67 over the next 12 months. The maximum analyst target price is USD 60 while the minimum anlayst target price is USD 32.
GH stock's Price/Earning ratio is 10.05.
Our analysis grades GH stock's Price / Earning ratio at D. This means that GH stock's Price/Earning ratio is above 36% of the stocks in the Diagnostics & Research sector in the NSD exchange.
Based on this GH may be fairly valued for its sector
The last closing price of GH's stock was USD 31.67.
The most recent market capitalization for GH is USD 4.40B.
Based on targets from 13 analysts, the average taret price for GH is projected at USD 42.67 over the next 12 months.
This means that GH's stock price may go up by +34.72% over the next 12 months.
We can't find any ETFs which contains Guardant Health Inc's stock.
As per our most recent records Guardant Health Inc has 1,768 Employees.
Guardant Health Inc's registered address is 3100 Hanover Street, Palo Alto, CA, United States, 94304.
You can get more information about it from Guardant Health Inc's website at https://guardanthealth.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for GH !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
